- Home
- PFLT vs IMMX Comparison
PFLT vs IMMX Comparison
Compare PFLT & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFLT | IMMX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 742.1M | 784.8M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PFLT | IMMX |
|---|---|---|
| Price | $6.94 | $7.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $9.57 | ★ $24.43 |
| AVG Volume (30 Days) | 833.9K | ★ 1.3M |
| Earning Date | 11-23-2026 | 11-10-2026 |
| Dividend Yield | ★ 14.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.15 | $2.85 |
| 52 Week High | $9.75 | $15.10 |
Technical Indicators
Market Signals| Indicator | PFLT | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 59.20 | 32.06 |
| Support Level | $6.15 | N/A |
| Resistance Level | $7.37 | $9.04 |
| Average True Range (ATR) | 0.17 | 0.53 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 96.87 | 4.06 |
Price Performance
Historical ComparisonAbout PFLT PennantPark Floating Rate Capital Ltd.
PennantPark Floating Rate Capital Ltd is a closed-end, externally managed, non-diversified investment company. Its investment objectives are to generate both current income and capital appreciation by investing in Floating Rate Loans and other investments made to U.S. middle-market companies. The company believes that Floating Rate Loans to U.S. middle-market companies offer attractive risk-reward to investors due to the limited amount of capital available for such companies and the potential for rising interest rates. The company generates revenue in the form of interest income on the debt securities and dividends.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.